<DOC>
	<DOCNO>NCT00845429</DOCNO>
	<brief_summary>Primary Objective : To describe immune response single administration 2 formulation investigational cell-based influenza vaccine healthy adult subject . Secondary Objective : To describe safety follow single administration 2 formulation investigational cell-based influenza vaccine healthy adult subject .</brief_summary>
	<brief_title>Immunogenicity Split , Cell-Based , Inactivated , Trivalent Influenza Vaccine Healthy Adult Subjects</brief_title>
	<detailed_description>This multi-center study healthy adult subject . All subject receive single dose one influenza vaccine formulation provide blood sample immunogenicity assessment .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy male female subject , age ≥ 18 &lt; 50 year day inclusion Informed consent form sign Able attend schedule visit comply trial procedure For woman childbearing potential : negative urine pregnancy test document use effective method contraception abstinence least four week pre vaccination three week postvaccination Exclusion Criteria : Subject currently breastfeed . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination . Planned participation another clinical trial present trial period . Prior participation Phase I trial FLU INTERPAN ( PER.C6 ) vaccine ( study GCE01 ) . Congenital history acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month . Systemic corticosteroid therapy except use topical inhalant corticosteroid Systemic hypersensitivity egg protein , chicken protein , vaccine component , history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion ( chronic illness may include , limited , cardiac , renal autoimmune disorder , diabetes ) . Receipt blood bloodderived product 3 month precede vaccination . Receipt vaccination 4 week precede vaccination , plan receipt vaccination 4 week follow trial vaccination . History influenza infection ( confirm either clinically , serologically microbiologically ) within 6 month precede vaccination . Previous vaccination influenza ( 6 month precede trial vaccination ) . Planned receipt 20072008 influenza vaccine . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . History GuillainBarré syndrome Current abuse alcohol drug addiction may interfere subject 's ability comply trial procedure Any condition opinion investigator would pose health risk participant interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Split-virion inactivated influenza vaccine</keyword>
	<keyword>cell-based vaccine</keyword>
	<keyword>Adults</keyword>
</DOC>